How to run clinical trials in the Middle East - why the GCC?
This article was originally published in Scrip
Executive Summary
A grouping of Middle Eastern countries came together under the auspices of the Gulf Co-operation Council in 1991. Its six members are Bahrain, Kuwait, Qatar, Oman, Saudi Arabia and the United Arab Emirates (UAE). The GCC countries co-operate in the field of healthcare, among others. The GCC market was valued by BioPlan at around $4 billion in 2008, with major growth expected.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.